180 related articles for article (PubMed ID: 27614514)
1. [Role of functional imaging in the definition of target volumes for lung cancer radiotherapy].
Thureau S; Hapdey S; Vera P
Cancer Radiother; 2016 Oct; 20(6-7):699-704. PubMed ID: 27614514
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
4. [Benefits of functional imaging in radiotherapy].
Vera P; Thureau S
Cancer Radiother; 2015 Oct; 19(6-7):538-42. PubMed ID: 26344445
[TBL] [Abstract][Full Text] [Related]
5. Workflow and radiation safety implications of (18)F-FDG PET/CT scans for radiotherapy planning.
Sam S; Shon IH; Vinod SK; Lin P; Lin M
J Nucl Med Technol; 2012 Sep; 40(3):175-7. PubMed ID: 22582005
[TBL] [Abstract][Full Text] [Related]
6. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
7. [The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].
Lõcsei Z; Hideghéty K; Farkas R; Bellyei S; Sárosi V; Sebestyén K; Sebestyén Z; Kovács P; Mangel L
Magy Onkol; 2011 Nov; 55(4):274-80. PubMed ID: 22128310
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
[TBL] [Abstract][Full Text] [Related]
9. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
10. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.
Scarfone C; Lavely WC; Cmelak AJ; Delbeke D; Martin WH; Billheimer D; Hallahan DE
J Nucl Med; 2004 Apr; 45(4):543-52. PubMed ID: 15073248
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer.
Grills IS; Yan D; Black QC; Wong CY; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):709-19. PubMed ID: 17197120
[TBL] [Abstract][Full Text] [Related]
12. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer.
Gondi V; Bradley K; Mehta M; Howard A; Khuntia D; Ritter M; Tomé W
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):187-95. PubMed ID: 17189070
[TBL] [Abstract][Full Text] [Related]
13. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.
Mac Manus MP; Hicks RJ
Semin Nucl Med; 2012 Sep; 42(5):308-19. PubMed ID: 22840596
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
[TBL] [Abstract][Full Text] [Related]
16. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition.
Schreurs LM; Busz DM; Paardekooper GM; Beukema JC; Jager PL; Van der Jagt EJ; van Dam GM; Groen H; Plukker JT; Langendijk JA
Dis Esophagus; 2010 Aug; 23(6):493-501. PubMed ID: 20113320
[TBL] [Abstract][Full Text] [Related]
17. Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation.
Zhou SM; Wong TZ; Marks LB
Med Phys; 2004 Sep; 31(9):2577-83. PubMed ID: 15487740
[TBL] [Abstract][Full Text] [Related]
18. Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora's box?
Devic S; Tomic N; Faria S; Menard S; Lisbona R; Lehnert S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1555-62. PubMed ID: 20646840
[TBL] [Abstract][Full Text] [Related]
19. Comparison between CT- and FDG-PET-defined target volumes for radiotherapy planning in head-and-neck cancers.
Henriques de Figueiredo B; Barret O; Demeaux H; Lagarde P; De-Mones-Del-Pujol E; Kantor G; de Clermont-Gallerande H; Richaud P; Fernandez P
Radiother Oncol; 2009 Dec; 93(3):479-82. PubMed ID: 19880207
[TBL] [Abstract][Full Text] [Related]
20. Critical review of PET-CT for radiotherapy planning in lung cancer.
Senan S; De Ruysscher D
Crit Rev Oncol Hematol; 2005 Dec; 56(3):345-51. PubMed ID: 15990331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
